Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

As psoriatic skin lesions often precede PsA, patients may discontinue dupilumab after developing psoriasis, preventing further progression. If PsA occurs first, the absence of skin symptoms may ...

Doctors prescribe JAK inhibitors for inflammatory conditions like rheumatoid arthritis and psoriatic arthritis. The FDA began approving JAK inhibitors to treat atopic dermatitis in 2022.

Adults with atopic dermatitis treated with upadacitinib had fewer major adverse cardiovascular events compared with background rates in real-world populations, adding to research supporting the ...

Primary Source JAMA Dermatology Source Reference: Lin T-L, et al "Psoriasis risk in patients with atopic dermatitis treated with dupilumab" JAMA Dermatol 2025; DOI: 10.1001/jamadermatol.2025.1578.

Send comments and news tips to [email protected]. Cite this: Edited by Deepa Varma. Dupilumab Linked to Higher Psoriasis Risk in Atopic Dermatitis - Medscape - June 19, 2025.